SABS compared with IRD: revenue, margins and what each company keeps, and the suppliers and customers both name

SABSSAB Biotherapeutics, Inc.

Mkt capRevenueRevenue

IRDOpus Genetics, Inc.

Mkt capRevenueRevenue

Compare

SABSSAB Biotherapeutics, Inc.

IRDOpus Genetics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

SABS

No earnings history for SABS.

IRD1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±41.2%▼−1.59%×0.04

= impliedSABS realized, solidIRD realized, hatchedOne scale, both sides: full bar = 42%× = |realized| ÷ impliedSource: market data

SABSSAB Biotherapeutics, Inc.

3.25▼−1.52%

Mkt cap$304.8MRevenue$114,698Q4 FY24Revenue—

IRDOpus Genetics, Inc.

3.92▲+5.85%

Regular sessionNov 3 '26

Mkt cap$307.8MRevenue$755,000Q2 FY26Revenue$14MFY25

Compare

Regular sessionNov 3 '26

SABSSAB Biotherapeutics, Inc.

IRDOpus Genetics, Inc.

3.25▼−1.52%

Price

3.92▲+5.85%

$304.8M

Mkt cap

$307.8M

Q4 FY24$114,698

Revenue

$755,000Q2 FY26

—

Revenue

$14MFY25

SABS3.25▼−1.52%vsIRD3.92▲+5.85%Regular sessionNov 3 '26